Horizon Therapeutics is owned by Amgen, a leading global biotechnology company.
Horizon Therapeutics, formerly known as Horizon Pharma plc, became a wholly-owned subsidiary of Amgen following a significant acquisition. This strategic move greatly expanded Amgen's portfolio, particularly in the realm of rare diseases and specialized therapeutic areas.
Understanding Horizon Therapeutics
Horizon Therapeutics has established itself as a prominent entity in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of medicines for rare, autoimmune, and severe inflammatory diseases. Their commitment lies in addressing unmet medical needs and improving the lives of patients suffering from challenging conditions.
Key Financial and Operational Metrics (2022 Data)
The following table provides a snapshot of Horizon Therapeutics' financial and operational scale prior to its acquisition:
| Metric | Value |
|---|---|
| Total Assets | US$9.11 billion |
| Total Equity | US$5.07 billion |
| Number of Employees | 2,115 |
These figures, based on 2022 data, reflect the substantial operational scale and financial strength that Horizon Therapeutics contributed to the Amgen organization. The company’s operations involved a dedicated team working across various functions, from research and development to commercialization, all aimed at delivering innovative therapies.
The Acquisition by Amgen
Amgen's acquisition of Horizon Therapeutics was a landmark event in the biotechnology sector. This acquisition underscores Amgen's commitment to strengthening its presence in specialized therapeutic areas and expanding its global reach.
- Strategic Rationale: Amgen aimed to diversify its revenue streams and gain access to Horizon's established and emerging therapies, particularly those for rare conditions where significant unmet patient needs exist.
- Market Impact: The deal was one of the largest in the pharmaceutical industry in recent years, signaling ongoing consolidation and strategic investments within the sector to build more comprehensive and specialized portfolios.
By integrating Horizon's innovative pipeline and commercial products, Amgen aims to enhance its ability to deliver transformative medicines to patients worldwide. The integration of Horizon Therapeutics into Amgen's structure is expected to leverage combined expertise and resources, fostering further innovation and advancing patient care in critical therapeutic areas.
